LARGO, Fla., Nov. 19 /PRNewswire-FirstCall/ -- GeoPharma, Inc. (the “Company”) GeoPharma, Inc. reached an agreement with Vetoquinol USA (http://www.vetoquinolusa.com/index1.html) for the marketing and distribution of Vetprofen(TM) nationwide. The agreement executed with GeoPharma’s wholly-owned subsidiary Belcher Pharmaceuticals represents GeoPharma’s first generic drug offering and features the active ingredient Carprofen. Carprofen is a non-steroidal anti-inflammatory drug (NSAID) that is used by veterinarians for the relief of pain and inflammation associated with osteoarthritis and post operative pain management in canines.
“Vetoquinol has long been a leader in the marketing and distribution of veterinary health products, so working with them was a logical choice to proliferate the acceptance of Vetprofen(TM) into the marketplace,” said GeoPharma CEO Mihir K. Taneja.
“Vetoquinol is very pleased to be partnering with Belcher Pharmaceuticals in an effort to market and distribute Vetprofen(TM) (Carprofen) in the United States,” stated Dan Schildgen, Director of Business Development for Vetoquinol USA. “This is an important opportunity for GeoPharma. Vetprofen as a companion animal pain management product is a very good fit for Vetoquinol’s business model, in terms of species, geographic region and therapeutic segment. The introduction of Vetprofen will enhance Vetoquinol’s presence in the U.S. market and complement its growing line of successful products.”
About Vetoquinol:
Founded in 1933, Vetoquinol is the 12th largest animal health company worldwide dedicated to both livestock and companion animals. The company distributes products in approximately 100 different countries and employs over 1200 people. Vetoquinol is publicly traded on the Euronext Exchange in Paris, France. Vetoquinol acquired Evsco Pharmaceuticals and Tomlyn Products to form Vetoquinol USA. Additionally in December of 2006 Vetoquinol acquired VET Solutions (http://www.vetsolutions.com/).
Vetoquinol’s business activities include research, manufacture, marketing and sales of medicines and nutraceuticals. Vetoquinol has developed expertise in 3 main areas: anti-infective, anti-inflammatory and cardio-nephrology. Leading products include Marbocyl(R) (anti-infective), Aurizon(R) (anti- infective), Prilium(R) (cardiology) and Tolfedine(R) (anti-inflammatory). Other successful offerings from Vetoquinol include Azodyl, Epakitin, Zentonil, Viralys/Enisyl-F, Nutrical, Fecalyzer, and Sebozole.
About GeoPharma Inc: GeoPharma, Inc. is a rapidly growing pharmaceutical company specializing in the manufacturing and distribution of over-the- counter, nutritional, generic drug and functional food products, as well as, health and beauty products for companies worldwide. This is accomplished by utilizing our wholly owned subsidiaries Innovative Health Products, Inc., Libi Labs, Belcher Pharmaceuticals, Inc. and Breakthrough Engineered Nutrition, Inc. Innovative Health Products and Libi Labs specialize in the development and manufacture of a broad range of nutritional supplements and cosmeceuticals. As a contract manufacturer, we develop and manufacture dietary supplements as well as health and beauty care products for distribution through various outlets. Belcher Pharmaceuticals, Inc is a state-of-the-art FDA-registered, drug development and manufacturing facility for generic and over-the-counter (“OTC”) drugs. Breakthrough Engineered Nutrition, Inc. develops markets and distributes its own branded dietary supplements. Currently, DEX-L10, DEX-C20, OxyFirm and Cortiloss are among Breakthrough’s top selling dietary products. Breakthrough’s products are distributed nationwide and internationally in specialty, food, drug and mass outlets, including Target, Wal-Mart, GNC, Walgreens, CVS, Rite Aid, Duane Reade and many others. We also have an established network of brokers and distributors strategically located across the United States and Canada. GeoPharma’s growth strategy is to capitalize on its manufacturing expertise to develop high margin generic or novel drugs for niche markets with high barriers to entry. GeoPharma’s competitive advantage lies in its ability to circumvent or overcome the challenges in these markets. For more about GeoPharma, Inc., go to our websites at www.geopharmainc.com, www.hoodiadexL10.com, and www.onlineihp.com
This press release may contain statements, which constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries’ expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company’s management as of the date hereof, and actual results may vary based upon future events, both within and without management’s control. Important factors that could cause such differences are described in the company’s periodic filings with the Securities and Exchange Commission.
CONTACT: Carol Dore-Falcone, VP-CFO of GeoPharma, +1-727-471-0850 x243,
IR@GeoPharmainc.com
Web site: http://www.onlineihp.com/
http://www.geopharmainc.com/
http://www.hoodiadexL10.com/
http://www.vetoquinolusa.com/index1.html/
http://www.vetsolutions.com//
